Published in N Engl J Med on February 07, 2013
Venous Thromboembolic Event (VTE) Prophylaxis in Medically Ill Patients (MAGELLAN) | NCT00571649
Direct oral anticoagulants: integration into clinical practice. Postgrad Med J (2014) 1.40
Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban. Clin Pharmacokinet (2014) 1.05
Rivaroxaban for thromboprophylaxis in acutely ill medical patients. N Engl J Med (2013) 0.93
Rivaroxaban for thromboprophylaxis in acutely ill medical patients. N Engl J Med (2013) 0.92
Rivaroxaban for thromboprophylaxis in acutely ill medical patients. N Engl J Med (2013) 0.92
Cancer and venous thromboembolic disease: from molecular mechanisms to clinical management. Curr Oncol (2014) 0.88
Edoxaban: an update on the new oral direct factor Xa inhibitor. Drugs (2014) 0.86
An updated review of target-specific oral anticoagulants used in stroke prevention in atrial fibrillation, venous thromboembolic disease, and acute coronary syndromes. J Am Heart Assoc (2013) 0.86
Safety of new oral anticoagulant drugs: a perspective. Ther Adv Drug Saf (2014) 0.85
Rivaroxaban for thromboprophylaxis in acutely ill medical patients. N Engl J Med (2013) 0.85
New oral anticoagulants: their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic events. Ther Clin Risk Manag (2015) 0.84
Update on Edoxaban for the Prevention and Treatment of Thromboembolism: Clinical Applications Based on Current Evidence. Adv Hematol (2015) 0.84
Infected total knee arthroplasty due to postoperative wound contamination with Pasteurella multocida. BMJ Case Rep (2013) 0.83
Intracranial hemorrhage risk with the new oral anticoagulants: a systematic review and meta-analysis. J Neurol (2014) 0.82
Profile of betrixaban and its potential in the prevention and treatment of venous thromboembolism. Vasc Health Risk Manag (2015) 0.81
Thrombo-prophylaxis in acutely ill medical and critically ill patients. Indian J Crit Care Med (2014) 0.81
Rivaroxaban for the treatment of pulmonary embolism. Adv Ther (2013) 0.81
Discovery of an intrinsic tenase complex inhibitor: Pure nonasaccharide from fucosylated glycosaminoglycan. Proc Natl Acad Sci U S A (2015) 0.79
Effectiveness and safety of expanded perioperative thromboprophylaxis in complex gynecologic surgery. Gynecol Oncol (2015) 0.78
Oral anticoagulants in the management of venous thromboembolism. Nat Rev Cardiol (2013) 0.78
Venous thromboembolism after community-acquired bacteraemia: a 20-year danish cohort study. PLoS One (2014) 0.77
New orally active anticoagulant agents for the prevention and treatment of venous thromboembolism in cancer patients. Ther Clin Risk Manag (2014) 0.77
Potential role of new anticoagulants for prevention and treatment of venous thromboembolism in cancer patients. Vasc Health Risk Manag (2013) 0.76
Risk of Gastrointestinal Bleeding with Rivaroxaban: A Comparative Study with Warfarin. Gastroenterol Res Pract (2016) 0.75
A survey of thrombosis experts evaluating practices and opinions regarding venous thromboprophylaxis in patients with active cancer hospitalized with an acute medical illness. Thromb J (2015) 0.75
Unmet Needs in Anticoagulant Therapy: Potential Role of Rivaroxaban. Cardiol Res (2015) 0.75
[Rivaroxaban for thromboprophylaxis inpatients with acute medical illness]. Rev Clin Esp (Barc) (2013) 0.75
Thromboprophylaxis after hospital discharge in acutely ill medical patients: need for trials in patients who are at high risk of venous thrombosis. J Thorac Dis (2017) 0.75
The Saudi clinical practice guideline for the prophylaxis of venous thromboembolism in medical and critically ill patients. Saudi Med J (2016) 0.75
Venous Thromboembolism in Cancer: An Update of Treatment and Prevention in the Era of Newer Anticoagulants. Front Cardiovasc Med (2016) 0.75
Prevention of venous thromboembolism in hospitalized acutely ill medical patients: focus on the clinical utility of (low-dose) fondaparinux. Drug Des Devel Ther (2013) 0.75
The new oral anti-coagulants and the phase 3 clinical trials - a systematic review of the literature. Thromb J (2013) 0.75
Respiratory review of 2014: pulmonary thromboembolism. Tuberc Respir Dis (Seoul) (2014) 0.75
Antithrombotic therapy for prophylaxis and treatment of venous thromboembolism in patients with cancer: review of the literature on current practice and emerging options. ESMO Open (2017) 0.75
Rendering factor Xa zymogen-like as a therapeutic strategy to treat bleeding. Curr Opin Hematol (2017) 0.75
Thromboprophylaxis with enoxaparin and direct oral anticoagulants in major orthopedic surgery and acutely ill medical patients: a meta-analysis. Intern Emerg Med (2017) 0.75
Effect of near-universal hospitalization-based prophylaxis on annual number of venous thromboembolism events in the US. Blood (2017) 0.75
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med (2012) 11.86
Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation. N Engl J Med (2015) 10.86
Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med (2010) 9.92
Fibrinolysis for patients with intermediate-risk pulmonary embolism. N Engl J Med (2014) 9.33
Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med (2009) 9.17
Third universal definition of myocardial infarction. J Am Coll Cardiol (2012) 8.59
Third universal definition of myocardial infarction. Circulation (2012) 8.47
Third universal definition of myocardial infarction. Eur Heart J (2012) 7.98
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med (2013) 7.76
Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med (2013) 6.71
A 2-h diagnostic protocol to assess patients with chest pain symptoms in the Asia-Pacific region (ASPECT): a prospective observational validation study. Lancet (2011) 5.61
Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet (2007) 5.41
Aspirin plus heparin or aspirin alone in women with recurrent miscarriage. N Engl J Med (2010) 5.06
Effectiveness of managing suspected pulmonary embolism using an algorithm combining clinical probability, D-dimer testing, and computed tomography. JAMA (2006) 4.75
Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy. Eur J Heart Fail (2010) 3.90
Periprocedural heparin bridging in patients receiving vitamin K antagonists: systematic review and meta-analysis of bleeding and thromboembolic rates. Circulation (2012) 3.74
The perioperative management of antithrombotic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 3.74
Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation (2013) 3.73
Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized controlled trial. JAMA (2004) 3.55
Cardio-renal syndromes: report from the consensus conference of the acute dialysis quality initiative. Eur Heart J (2009) 3.52
Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology. Eur Heart J (2005) 3.50
Consensus on circulatory shock and hemodynamic monitoring. Task force of the European Society of Intensive Care Medicine. Intensive Care Med (2014) 3.37
State of the art: using natriuretic peptide levels in clinical practice. Eur J Heart Fail (2008) 3.35
Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. N Engl J Med (2011) 3.30
Bidirectional relation between inflammation and coagulation. Circulation (2004) 3.00
Effect of recombinant activated factor VII on perioperative blood loss in patients undergoing retropubic prostatectomy: a double-blind placebo-controlled randomised trial. Lancet (2003) 2.86
The optimal intensity of vitamin K antagonists in patients with mechanical heart valves: a meta-analysis. J Am Coll Cardiol (2003) 2.71
Left cardiac sympathetic denervation in the management of high-risk patients affected by the long-QT syndrome. Circulation (2004) 2.63
Year in review in Intensive Care Medicine 2011: III. ARDS and ECMO, weaning, mechanical ventilation, noninvasive ventilation, pediatrics and miscellanea. Intensive Care Med (2012) 2.52
Prevention of venous thromboembolism in the orthopedic surgery patient. Cleve Clin J Med (2008) 2.51
Safe exclusion of pulmonary embolism using the Wells rule and qualitative D-dimer testing in primary care: prospective cohort study. BMJ (2012) 2.38
Comparing the diagnostic performance of 2 clinical decision rules to rule out deep vein thrombosis in primary care patients. Ann Fam Med (2011) 2.34
The incidence of recurrent venous thromboembolism after treatment with vitamin K antagonists in relation to time since first event: a meta-analysis. Arch Intern Med (2003) 2.33
Diagnostic strategies for excluding pulmonary embolism in clinical outcome studies. A systematic review. Ann Intern Med (2003) 2.33
The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol (2005) 2.31
Performance of 4 clinical decision rules in the diagnostic management of acute pulmonary embolism: a prospective cohort study. Ann Intern Med (2011) 2.28
Acute pulmonary embolism: sensitivity and specificity of ventilation-perfusion scintigraphy in PIOPED II study. Radiology (2008) 2.25
Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol (2003) 2.23
Rapidly progressive diaphragmatic weakness and injury during mechanical ventilation in humans. Am J Respir Crit Care Med (2010) 2.17
Preoperative or postoperative start of prophylaxis for venous thromboembolism with low-molecular-weight heparin in elective hip surgery? Arch Intern Med (2002) 2.16
High incidence of myocardial ischemia during postpartum hemorrhage. Anesthesiology (2004) 2.16
Direct thrombin inhibitors. N Engl J Med (2005) 2.15
Questing for circadian dependence in ST-segment-elevation acute myocardial infarction: a multicentric and multiethnic study. Circ Res (2013) 2.13
Risk of deep vein thrombosis and pulmonary embolism in asthma. Eur Respir J (2012) 2.08
International REgistry to assess medical Practice with lOngitudinal obseRvation for Treatment of Heart Failure (REPORT-HF): rationale for and design of a global registry. Eur J Heart Fail (2015) 2.03
Echocardiography in the ICU: time for widespread use! Intensive Care Med (2005) 2.03
Effects on coagulation and fibrinolysis induced by influenza in mice with a reduced capacity to generate activated protein C and a deficiency in plasminogen activator inhibitor type 1. Circ Res (2006) 1.95
Prognostic value of echocardiographically assessed right ventricular dysfunction in patients with pulmonary embolism. Arch Intern Med (2004) 1.92
Propensity scores in intensive care and anaesthesiology literature: a systematic review. Intensive Care Med (2010) 1.89
Systematic review of the use of retrievable inferior vena cava filters. J Vasc Interv Radiol (2011) 1.83
Efficacy and safety of recombinant factor VIIa for treatment of severe bleeding: a systematic review. Crit Care Med (2005) 1.82
Longitudinal evaluation of health plan cost per venous thromboembolism or bleed event in patients with a prior venous thromboembolism event during hospitalization. J Manag Care Pharm (2005) 1.81
Use of a clinical decision rule in combination with D-dimer concentration in diagnostic workup of patients with suspected pulmonary embolism: a prospective management study. Arch Intern Med (2002) 1.81
Microvascular effects of heart rate control with esmolol in patients with septic shock: a pilot study. Crit Care Med (2013) 1.81
Lowered B-type natriuretic peptide in response to levosimendan or dobutamine treatment is associated with improved survival in patients with severe acutely decompensated heart failure. J Am Coll Cardiol (2009) 1.76
Liver function abnormalities, clinical profile, and outcome in acute decompensated heart failure. Eur Heart J (2012) 1.70
Incremental value of biomarkers to clinical variables for mortality prediction in acutely decompensated heart failure: the Multinational Observational Cohort on Acute Heart Failure (MOCA) study. Int J Cardiol (2013) 1.69
An epidemiological study on the prevalence of atrial fibrillation in the Chinese population of mainland China. J Epidemiol (2008) 1.68
Cardiac resynchronisation as a rescue therapy in patients with catecholamine-dependent overt heart failure: results from a short and mid-term study. Eur J Heart Fail (2008) 1.68
Factors at admission associated with bleeding risk in medical patients: findings from the IMPROVE investigators. Chest (2010) 1.67
Effects of a telephone-based psychosocial intervention for patients awaiting lung transplantation. Chest (2002) 1.66
The severity of trauma determines the immune response to PF4/heparin and the frequency of heparin-induced thrombocytopenia. Blood (2009) 1.65
Derivation and validation of multimarker prognostication for normotensive patients with acute symptomatic pulmonary embolism. Am J Respir Crit Care Med (2014) 1.63
Thrombotic risk during oral contraceptive use and pregnancy in women with factor V Leiden or prothrombin mutation: a rational approach to contraception. Blood (2011) 1.63
Selexipag for the Treatment of Pulmonary Arterial Hypertension. N Engl J Med (2015) 1.62
Deep-vein thrombosis: a United States cost model for a preventable and costly adverse event. Thromb Haemost (2011) 1.61
Impact of diuretic dosing on mortality in acute heart failure using a propensity-matched analysis. Eur J Heart Fail (2011) 1.60
Impaired plasma B-type natriuretic peptide clearance in human septic shock. Crit Care Med (2008) 1.59
Statin treatment and the risk of recurrent pulmonary embolism. Eur Heart J (2013) 1.58
Video-assisted thoracoscopic left cardiac sympathetic denervation: a reliable minimally invasive approach for congenital long-QT syndrome. Ann Thorac Surg (2008) 1.58
Acute heart failure in patients with diabetes mellitus: clinical characteristics and predictors of in-hospital mortality. Int J Cardiol (2011) 1.57
Activation of peroxisome proliferator-activated receptor-alpha by fenofibrate prevents myocardial dysfunction during endotoxemia in rats. Crit Care Med (2007) 1.57
Cardiovascular risk assessment in haemophilia patients. Thromb Haemost (2010) 1.57
ACCF/AHA clinical competence statement on cardiac imaging with computed tomography and magnetic resonance: a report of the American College of Cardiology Foundation/American Heart Association/American College of Physicians Task Force on Clinical Competence and Training. J Am Coll Cardiol (2005) 1.56
Clinical picture and risk prediction of short-term mortality in cardiogenic shock. Eur J Heart Fail (2015) 1.56
Use of oral glucocorticoids and the risk of pulmonary embolism: a population-based case-control study. Chest (2013) 1.55
Identification and predictive value of interleukin-6+ interleukin-10+ and interleukin-6- interleukin-10+ cytokine patterns in ST-elevation acute myocardial infarction. Circ Res (2012) 1.55
High-sensitivity C-reactive protein is within normal levels at the very onset of first ST-segment elevation acute myocardial infarction in 41% of cases: a multiethnic case-control study. J Am Coll Cardiol (2011) 1.53
Cinaciguat, a soluble guanylate cyclase activator: results from the randomized, controlled, phase IIb COMPOSE programme in acute heart failure syndromes. Eur J Heart Fail (2012) 1.53
Validity and clinical utility of the simplified Wells rule for assessing clinical probability for the exclusion of pulmonary embolism. Thromb Haemost (2009) 1.51
Experts' recommendations for the management of adult patients with cardiogenic shock. Ann Intensive Care (2015) 1.51
Risk profile and clinical outcome of symptomatic subsegmental acute pulmonary embolism. Blood (2013) 1.51
Risk of recurrent venous thrombosis in homozygous carriers and double heterozygous carriers of factor V Leiden and prothrombin G20210A. Circulation (2010) 1.50
Thrombosis prophylaxis in patient populations with a central venous catheter: a systematic review. Arch Intern Med (2003) 1.49
Factors associated with the mediastinal spread of cervical necrotizing fasciitis. Ann Thorac Surg (2011) 1.48
Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls. Thromb Haemost (2011) 1.47
Beneficial association of β-blocker therapy on recovery from severe acute heart failure treatment: data from the Survival of Patients With Acute Heart Failure in Need of Intravenous Inotropic Support trial. Crit Care Med (2011) 1.45
Clinical profile, contemporary management and one-year mortality in patients with severe acute heart failure syndromes: The EFICA study. Eur J Heart Fail (2006) 1.45